Evidence map›Paper›PMID 35536495›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence.

Claudio Liguori, Mariana Fernandes, Rocco Cerroni, Raffaella Ludovisi, Nicola Biagio Mercuri, Alessandro Stefani, Mariangela Pierantozzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Exploring the role of melatonin in managing sleep and motor symptoms in Parkinson's disease: a pooled analysis of double-blinded randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudio LiguoriNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. dott.claudioliguori@yahoo.it.ORCID http://orcid.org/0000-0003-2845-1332
Mariana FernandesSleep Medicine Centre, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.ORCID http://orcid.org/0000-0002-7005-2805
Rocco CerroniNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Raffaella LudovisiSleep Medicine Centre, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Nicola Biagio MercuriNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Alessandro StefaniNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Mariangela PierantozziNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSleep-related symptoms, especially insomnia, are frequently reported by patients with Parkinson's disease (PD) and can markedly affect motor symptoms and impair patients' quality of life. Melatonin has been shown to improve sleep in PD patients. This pilot study aimed at evaluating the effects of a 3-month treatment with 2 mg melatonin prolonged-release (PR) on sleep and motor disability in PD patients. MATERIALS AND

methodsTwelve PD patients under stable antiparkinsonian treatment were enrolled in the study. Before treatment (T0), motor dysfunction was assessed with Unified Parkinson's Disease Rating Scale (UPDRS-III) and sleep architecture with polysomnography. Subjective sleep quality was also assessed through Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence with Epworth Sleepiness Scale (ESS). Patients then started melatonin PR and all measures were repeated at the end of treatment after 3 months (T1).

resultsSleep latency significantly decreased from T0 to T1, but no other significant differences were found in PSG parameters. Melatonin PR treatment significantly reduced the ESS scores from T0 to T1, while the PSQI scores presented a trend of improvement from T0 to T1. Motor dysfunction was not improved by melatonin PR, although there was a trend in decreasing UPDRS-III. Both clinical global improvement and patient clinical global impression documented an improvement in insomnia symptoms at T1.

conclusionsThese findings suggest that melatonin may improve sleep symptoms in PD patients, although further evidence is needed in larger controlled studies to confirm these results and explore the possible direct and indirect influence of sleep improvement on motor dysfunction.

Indexed as

MelatoninMotor DisordersParkinson DiseasePersons with DisabilitiesSleep Initiation and Maintenance DisordersSleep Wake DisordersHumansPilot ProjectsQuality of LifeSleepMelatoninDaytime sleepinessInsomniaMelatoninMotor symptomsMovement disorderPolysomnography

Identifiers

PMID35536495
PMCPMC9385777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.